Alternative titles; symbols
Other entities represented in this entry:
SNOMEDCT: 738771004; ORPHA: 753;
| Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
|---|---|---|---|---|---|---|
| 2p23.1 | Pseudovaginal perineoscrotal hypospadias | 264600 | Autosomal recessive | 3 | SRD5A2 | 607306 |
A number sign (#) is used with this entry because pseudovaginal perineoscrotal hypospadias (PPSH) is caused by homozygous or compound heterozygous mutation in the steroid 5-alpha-reductase-2 gene (SRD5A2; 607306) on chromosome 2p23.
Pseudovaginal perineoscrotal hypospadias is a form of male pseudohermaphroditism in which 46,XY males show ambiguous genitalia at birth, including perineal hypospadias and a blind perineal pouch, and develop masculinization at puberty. The name of the disorder stems from the finding of a blind-ending perineal opening resembling a vagina and a severely hypospadiac penis with the urethra opening onto the perineum.
De Vaal (1955) reported 3 brothers who were thought for a time to be girls. The parents and grandparents on one side were first cousins, and the great-grandparents were also related. Simpson et al. (1971) described a family with 3 affected brothers whose parents were double first cousins. Each of the affected sibs had an XY karyotype and ambiguous genitalia, leading to rearing as females. No breast development or menstruation occurred at puberty, and instead typical masculinization was observed.
Opitz et al. (1972) concluded that the consanguineous family reported by Philip and Trolle (1965) had pseudovaginal perineoscrotal hypoplasia.
PPSH can be difficult to distinguish from the incomplete testicular feminization syndrome (PAIS; 312300), also known as Reifenstein syndrome, especially in the young child. The distinction is obviously important since PPSH is a male-limited autosomal recessive with a recurrence risk of 1 in 8, whereas PAIS is X-linked recessive as is the complete syndrome (AIS; 300068). Wilson et al. (1974) chose to refer to PPSH as type 2 familial incomplete male pseudohermaphroditism, type 1 being Reifenstein syndrome. PPSH resembles the most severe form of type 1 incomplete male pseudohermaphroditism, but differs from it by the lack of breasts and by its autosomal inheritance. Dihydrotestosterone (DHT) formation is defective in this condition. Testosterone and estrogen levels are normal, hence the lack of gynecomastia. Other evidence as well suggests that DHT is important to external virilization.
In a village in the Dominican Republic, Imperato-McGinley et al. (1974) studied 12 families with 22 male pseudohermaphrodites. The affected males were born with ambiguous genitalia and masculinized at puberty without breast development. The testes were normal histologically. The patients had no mullerian structures, complete wolffian differentiation, small phallus, bifid scrotum, urogenital sinus with perineal hypospadias and blind vaginal pouch. At puberty, they showed male habitus with excellent muscular development, voice change, enlargement of phallus and production of semen, but small prostate and scanty beard. Plasma testosterone was normal; plasma 5-alpha-dihydrotestosterone was low. An abnormally small amount of radioactive testosterone was converted to dihydrotestosterone. One woman studied showed the same biochemical defect.
The disorder has been found in blacks, whites, American Indians, and Latin Americans, as well as in families from Malta, Jordan, and Pakistan. Imperato-McGinley et al. (1991) described a cluster of male pseudohermaphrodites in the Simbari Anga linguistic group in the Eastern Highlands of Papua New Guinea. Their studies revealed a phenotypic and biochemical profile similar to that in patients studied in the Dominican Republic, except for a greater abundance of facial and body hair. DHT is responsible for masculinization of the external genitalia of the fetus and for masculinization at puberty. The virilization at puberty in PPSH may be related to the facts that the reductase is not completely absent and that low levels of DHT are found in plasma.
Leshin et al. (1978) suggested the existence of two forms of 5-alpha-reductase deficiency. In one form (represented by a family in Dallas and by the Dominican kindred), an abnormal Km for substrate and low activity suggested a structural alteration in the enzyme. In a second form, represented by a Los Angeles family, activity in the biopsy specimen was not detectable, although cultured fibroblasts showed normal activity with normal Km for testosterone. The authors postulated either a structural mutation that was corrected or compensated for in tissue culture or a regulatory mutant. These persons have plasma testosterone levels in the high normal range. Although raised as girls, most change to a male-gender identity at puberty. This indicates that the effects of testosterone on the brain override sociocultural factors. Hydroxylation at the fifth position, converting testosterone to dihydrotestosterone, seems like an insignificant change; however, functionally it produces a marked change because in steric configuration the molecule becomes much flatter and fits its receptor in a way that testosterone cannot (Wilson, 1981). Wilson (1981) studied 14 families; in 11, the enzyme was virtually undetectable. In the other 3, a qualitative abnormality of the enzyme was found.
Chavez et al. (2000) performed DNA analyses in 2 unrelated subjects with SRD5A enzyme deficiency and found differences in the mode of transmission for the disease. Their data showed that in both families the fathers were carriers for a glu197-to-asp mutation (E197D; 607306.0014), whereas the mothers were carriers for a pro212-to-arg mutation (P212R; 607306.0013). While patient 1 was identified as a compound heterozygote for both alterations, patient 2 was found to be homozygous for the paternal mutation. The reduction to homozygosity for the E197D mutation, as confirmed by restriction analysis, supported this view. The authors concluded that their study gives evidence of the first case of SRD5A deficiency resulting from uniparental disomy and reveals an alternate mechanism whereby this enzymatic disorder can be derived from a single parent.
Thigpen et al. (1993) provided evidence that the 5-alpha-reductase type 1 enzyme is responsible for the virilization in type 2-deficient subjects during puberty.
Price et al. (1984) presented evidence that high dose androgen therapy may improve virilization, self-image, and sexual performance in patients with alpha-reductase deficiency who have male-gender behavior and in those patients with Reifenstein syndrome (312300) who have normal amounts of a qualitatively abnormal androgen receptor.
A number of male pseudohermaphrodites have married and expressed a desire to father a child. However, a deficiency in dihydrotestosterone production not only impairs differentiation of male external genitalia but also affects the development and secretory function of the prostate and seminal vesicles. Consequently, affected adults have a rudimentary prostate and underdeveloped seminal vesicles, resulting in a highly viscous semen and an extremely low volume of ejaculate, although sperm counts may be normal. Katz et al. (1997) described the use of intrauterine insemination with sperm from a man with this disorder and a history of infertility. The first pregnancy gave rise to a normal son; the second pregnancy produced fraternal twins. All 3 children were heterozygous for the father's C-to-T mutation in exon 5 of the SRD5A2 gene.
In 2 related men with PPSH from the Simbari Anga linguistic group in the Highlands of Papua New Guinea, Andersson et al. (1991) found deletion of most of the SRD5A2 gene (607306.0001).
In 3 Japanese patients with micropenis, Sasaki et al. (2003) identified homozygous or compound heterozygous mutations in the SRD5A2 gene (see, e.g., 607306.0015-607306.0016).
Exclusion Studies
Jenkins et al. (1992) showed that the enzyme encoded by SRD5A1 (184753) on chromosome 5 is not the site of the defect in classic PPSH; in 16 patients with deficiency of 5-alpha-reductase, no SRD5A1 gene rearrangements were detected; in 5 of these subjects, sequence analysis revealed no mutation in the coding regions of the SRD5A1 gene; linkage studies with a RFLP showed recombination and heterozygosity, which would not occur in an autosomal recessive disease. These findings provided evidence for the existence of 2 steroid 5-alpha-reductase enzymes (see SRD5A2; 607306).
Andersson, S., Berman, D. M., Jenkins, E. P., Russell, D. W. Deletion of steroid 5-alpha-reductase 2 gene in male pseudohermaphroditism. Nature 354: 159-161, 1991. [PubMed: 1944596] [Full Text: https://doi.org/10.1038/354159a0]
Boudon, C., Lobaccaro, J. M., Lumbroso, S., Ogur, G., Ocal, G., Belon, C., Sultan, C. A new deletion of the 5-alpha-reductase type 2 gene in a Turkish family with 5-alpha-reductase deficiency. Clin. Endocr. 43: 183-188, 1995. [PubMed: 7554313] [Full Text: https://doi.org/10.1111/j.1365-2265.1995.tb01913.x]
Cai, L.-Q., Zhu, Y.-S., Katz, M. D., Herrera, C., Baez, J., DeFillo-Ricart, M., Shackleton, C. H. L., Imperato-McGinley, J. 5-Alpha-reductase-2 gene mutations in the Dominican Republic. J. Clin. Endocr. Metab. 81: 1730-1735, 1996. [PubMed: 8626825] [Full Text: https://doi.org/10.1210/jcem.81.5.8626825]
Can, S., Zhu, Y.-S., Cai, L.-Q., Ling, Q., Katz, M. D., Akgun, S., Shackleton, C. H. L., Imperato-McGinley, J. The identification of 5-alpha-reductase-2 and 17-beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred. J. Clin. Endocr. Metab. 83: 560-569, 1998. [PubMed: 9467575] [Full Text: https://doi.org/10.1210/jcem.83.2.4535]
Chavez, B., Valdez, E., Vilchis, F. Uniparental disomy in steroid 5-alpha-reductase 2 deficiency. J. Clin. Endocr. Metab. 85: 3147-3150, 2000. [PubMed: 10999800] [Full Text: https://doi.org/10.1210/jcem.85.9.6786]
De Vaal, O. M. Genital intersexuality in three brothers, connected with consanguineous marriages in the three previous generations. Acta Paediat. 44: 35-39, 1955.
Forti, G., Falchetti, A., Santoro, S., Davis, D. L., Wilson, J. D., Russell, D. W. Steroid 5 alpha-reductase 2 deficiency: virilization in early infancy may be due to partial function of mutant enzyme. Clin. Endocr. 44: 477-482, 1996. [PubMed: 8706317] [Full Text: https://doi.org/10.1046/j.1365-2265.1996.673496.x]
Greene, S. A., Symes, E., Brook, C. G. D. 5-Alpha-reductase deficiency causing male pseudohermaphroditism. Arch. Dis. Child. 53: 751-753, 1978. [PubMed: 718244] [Full Text: https://doi.org/10.1136/adc.53.9.751]
Hochberg, Z., Chayen, R., Reiss, N., Falik, Z., Makler, A., Munichor, M., Farkas, A., Goldfarb, H., Ohana, N., Hiort, O. Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5-alpha-reductase 2 deficiency. J. Clin. Endocr. Metab. 81: 2821-2827, 1996. [PubMed: 8768837] [Full Text: https://doi.org/10.1210/jcem.81.8.8768837]
Imperato-McGinley, J., Gautier, T. Inherited 5-alpha-reductase deficiency in man. Trends Genet. 2: 130-133, 1986.
Imperato-McGinley, J., Guerrero, L., Gautier, T., German, J. L., Peterson, R. E. Steroid-5-alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism. In: Bergsma, D.: Genetic Forms of Hypogonadism. New York: National Foundation-March of Dimes (pub.) 1975. Pp. 91-103.
Imperato-McGinley, J., Guerrero, L., Gautier, T., Peterson, R. E. Steroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186: 1213-1215, 1974. [PubMed: 4432067] [Full Text: https://doi.org/10.1126/science.186.4170.1213]
Imperato-McGinley, J., Miller, M., Wilson, J. D., Peterson, R. E., Shackleton, C., Gajdusek, D. C. A cluster of male pseudohermaphrodites with 5-alpha-reductase deficiency in Papua New Guinea. Clin. Endocr. 34: 293-298, 1991. [PubMed: 1831738] [Full Text: https://doi.org/10.1111/j.1365-2265.1991.tb03769.x]
Imperato-McGinley, J., Peterson, R. E., Gautier, T., Sturla, E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5-alpha-reductase deficiency. New Eng. J. Med. 300: 1233-1237, 1979. [PubMed: 431680] [Full Text: https://doi.org/10.1056/NEJM197905313002201]
Imperato-McGinley, J., Peterson, R. E., Leshin, M., Griffin, J. E., Cooper, G., Draghi, S., Berenyi, M., Wilson, J. D. Steroid 5 alpha-reductase deficiency in a 65-year-old male pseudohermaphrodite: the natural history, ultrastructure of the testes, and evidence for inherited enzyme heterogeneity. J. Clin. Endocr. Metab. 50: 15-22, 1980. [PubMed: 7350177] [Full Text: https://doi.org/10.1210/jcem-50-1-15]
Jakimiuk, A. J., Weitsman, S. R., Magoffin, D. A. 5-alpha-reductase activity in women with polycystic ovary syndrome. J. Clin. Endocr. Metab. 84: 2414-2418, 1999. [PubMed: 10404813] [Full Text: https://doi.org/10.1210/jcem.84.7.5863]
Jenkins, E. P., Andersson, S., Imperato-McGinley, J., Wilson, J. D., Russell, D. W. Genetic and pharmacological evidence for more than one human steroid 5-alpha-reductase. J. Clin. Invest. 89: 293-300, 1992. [PubMed: 1345916] [Full Text: https://doi.org/10.1172/JCI115574]
Katz, M. D., Kligman, I., Cai, L.-Q., Zhu, Y.-S., Fratianni, C. M., Zervoudakis, I., Rosenwaks, Z., Imperato-McGinley, J. Paternity in intrauterine insemination with sperm from a man with 5-alpha-reductase-2 deficiency. New Eng. J. Med. 336: 994-997, 1997. [PubMed: 9077378] [Full Text: https://doi.org/10.1056/NEJM199704033361404]
Komp, D. M. Dr. Imperato-McGinley. (Letter) Lancet 314: 262 only, 1979. Note: Originally Volume II.
Leshin, M., Griffin, J. E., Wilson, J. D. 5-Alpha-reductase deficiency: evidence for genetic heterogeneity. (Abstract) Clin. Res. 26: 47A only, 1978.
Leshin, M., Griffin, J. E., Wilson, J. D. Hereditary male pseudohermaphroditism associated with an unstable form of 5-alpha-reductase. J. Clin. Invest. 62: 685-691, 1978. [PubMed: 29056] [Full Text: https://doi.org/10.1172/JCI109176]
Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., Reichardt, J. K. V. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975-978, 1999. [PubMed: 10501358] [Full Text: https://doi.org/10.1016/S0140-6736(98)11282-5]
Moore, R. J., Griffin, J. E., Wilson, J. D. Diminished 5-alpha-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2. J. Biol. Chem. 250: 7168-7172, 1975. [PubMed: 240819]
Nordenskjold, A., Ivarsson, S.-A. Molecular characterization of 5-alpha-reductase type 2 deficiency and fertility in a Swedish family. J. Clin. Endocr. Metab. 83: 3236-3238, 1998. [PubMed: 9745434] [Full Text: https://doi.org/10.1210/jcem.83.9.5125]
Nordenskjold, A., Magnus, O., Aagenaes, O., Knudtzon, J. Homozygous mutation (A228T) in the 5-alpha-reductase type 2 gene in a boy with 5-alpha-reductase deficiency: genotype-phenotype correlations. Am. J. Med. Genet. 80: 269-272, 1998. [PubMed: 9843052]
Opitz, J. M., Simpson, J. L., Sarto, G. E., Summitt, R. L., New, M., German, J. Pseudovaginal perineoscrotal hypospadias. Clin. Genet. 3: 1-26, 1972. [PubMed: 5013863] [Full Text: https://doi.org/10.1111/j.1399-0004.1972.tb01721.x]
Peterson, R. E., Imperato-McGinley, J., Gautier, T., Sturla, E. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am. J. Med. 62: 170-191, 1977. [PubMed: 835597] [Full Text: https://doi.org/10.1016/0002-9343(77)90313-8]
Philip, J., Trolle, D. Familial male hermaphroditism with delayed and partial masculinization. Am. J. Obstet. Gynec. 93: 1076-1083, 1965. [PubMed: 4221283] [Full Text: https://doi.org/10.1016/0002-9378(65)90175-4]
Pinsky, L., Kaufman, M., Straisfeld, C., Zilahi, B., Hall, C. S.-G. 5-Alpha-reductase activity of genital and nongenital skin fibroblasts from patients with 5-alpha-reductase deficiency, androgen insensitivity, or unknown forms of pseudohermaphroditism. Am. J. Med. Genet. 1: 407-416, 1978. [PubMed: 665726] [Full Text: https://doi.org/10.1002/ajmg.1320010404]
Price, P., Wass, J. A. H., Griffin, J. E., Leshin, M., Savage, M. O., Large, D. M., Bu'Lock, D. E., Anderson, D. C., Wilson, J. D., Besser, G. M. High dose androgen therapy in male pseudohermaphroditism due to 5-alpha-reductase deficiency and disorders of the androgen receptor. J. Clin. Invest. 74: 1496-1508, 1984. [PubMed: 6480833] [Full Text: https://doi.org/10.1172/JCI111563]
Sasaki, G., Ogata, T., Ishii, T., Kosaki, K., Sato, S., Homma, K., Takahashi, T., Hasegawa, T., Matsuo, N. Micropenis and the 5-alpha-reducta se-2 (SRD5A2) gene: mutation and V89L polymorphism analysis in 81 Japanese patients. J. Clin. Endocr. Metab. 88: 3431-3436, 2003. [PubMed: 12843198] [Full Text: https://doi.org/10.1210/jc.2002-021415]
Savage, M. O., Preece, M. A., Jeffcoate, S. L., Ransley, P. G., Rumsby, G., Mansfield, M. D., Williams, D. I. Familial male pseudohermaphroditism due to deficiency of 5-alpha-reductase. Clin. Endocr. 12: 397-406, 1980. [PubMed: 7379320] [Full Text: https://doi.org/10.1111/j.1365-2265.1980.tb02727.x]
Simpson, J. L., New, M., Peterson, R. E., German, J. Pseudovaginal perineoscrotal hypospadias (PPSH) in sibs. Birth Defects Orig. Art. Ser. VII(6): 140-144, 1971.
Soderstrom, T. G., Bjelfman, C., Brekkan, E., Ask, B., Egevad, L., Norlen, B. J., Rane, A. Messenger ribonucleic acid levels of steroid 5-alpha-reductase 2 in human prostate predict the enzyme activity. J. Clin. Endocr. Metab. 86: 855-858, 2001. [PubMed: 11158057] [Full Text: https://doi.org/10.1210/jcem.86.2.7224]
Thigpen, A. E., Davis, D. L., Gautier, T., Imperato-McGinley, J., Russell, D. W. The molecular basis of steroid 5-alpha-reductase deficiency in a large Dominican kindred. New Eng. J. Med. 327: 1216-1219, 1992. [PubMed: 1406794] [Full Text: https://doi.org/10.1056/NEJM199210223271706]
Thigpen, A. E., Davis, D. L., Milatovich, A., Mendonca, B. B., Imperato-McGinley, J., Griffin, J. E., Francke, U., Wilson, J. D., Russell, D. W. The molecular genetics of steroid 5-alpha-reductase 2 deficiency. J. Clin. Invest. 90: 799-809, 1992. [PubMed: 1522235] [Full Text: https://doi.org/10.1172/JCI115954]
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., Russell, D. W. Tissue distribution and ontogeny of steroid 5-alpha-reductase isozyme expression. J. Clin. Invest. 92: 903-910, 1993. [PubMed: 7688765] [Full Text: https://doi.org/10.1172/JCI116665]
Vilchis, F., Canto, P., Chavez, B., Ulloa-Aguirre, A., Mendez, J. P. Molecular analysis of the 5-alpha-steroid reductase type 2 gene in a family with deficiency of the enzyme. Am. J. Med. Genet. 69: 69-72, 1997. [PubMed: 9066886]
Walsh, P. C., Madden, J. D., Harrod, M. J., Goldstein, J. L., MacDonald, P. C., Wilson, J. D. Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. New Eng. J. Med. 291: 944-949, 1974. [PubMed: 4413434] [Full Text: https://doi.org/10.1056/NEJM197410312911806]
Wilson, J. D., Harrod, M. J., Goldstein, J. L., Hemsell, D. L., MacDonald, P. C. Familial incomplete male pseudohermaphroditism type I: evidence for androgen resistance in a family with the Reifenstein syndrome. New Eng. J. Med. 290: 1097-1103, 1974. [PubMed: 4821173] [Full Text: https://doi.org/10.1056/NEJM197405162902001]
Wilson, J. D. Personal Communication. Dallas, Texas 10/30/1981.